

WHAT IS CLAIMED IS:

1. The isolated or recombinant polypeptide comprising the amino acid sequence of SEQ ID NO: 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 37, 39, 41, 43, or 45, or an antigenic fragment thereof.
2. An isolated or recombinant nucleic acid encoding the polypeptide of Claim 1.
3. The nucleic acid of Claim 2, further comprising an expression vector.
4. A binding compound that specifically binds to the polypeptide or the antigenic fragment of Claim 1.
5. The binding compound of Claim 4, wherein said binding compound comprises an antibody or antibody fragment.
6. The binding compound of Claim 4, wherein said binding compound further comprises a detectable label or a purification tag.
7. The binding compound of Claim 4, wherein said binding compound is attached to a solid support.
8. A natural allelic variant of the polypeptide of Claim 1.
9. A binding compound that specifically binds to a ligand of SEQ ID NO: 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 37, 39, 41, 43, or 45.
10. The binding compound of Claim 9, wherein said binding compound is an antibody or antibody fragment.
11. The binding compound of Claim 9, wherein said binding compound is a soluble antigenic fragment of SEQ ID NO: 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 37, 39, 41, 43, or 45.
12. The binding compound of Claim 9, wherein said binding compound is detectably labeled.

13. The binding compound of Claim 9, wherein said binding compound further comprising an oligopeptide purification tag or a polypeptide purification tag.

5 14. The binding compound of Claim 9, wherein said binding compound is attached to a solid support.

15. A method of treating a patient having sepsis or septic shock comprising administering to said patient a binding compound which binds specifically to a ligand of SEQ ID NO: 8.

10 16. The method of Claim 15, wherein said binding compound is an antibody, an antibody fragment, or a soluble antigenic fragment of SEQ ID NO: 8.

15 17. A method of treating a patient having sepsis or septic shock comprising administering to said patient a binding compound which binds specifically to a ligand of SEQ ID NO: 26.

20 18. The method of Claim 17, wherein said binding compound is an antibody, an antibody fragment, or a soluble antigenic fragment of SEQ ID NO: 26.

25 19. A method of treating a patient having an interferon- α treatable condition, comprising administering to the patient an antibody or antibody fragment which binds specifically to SEQ ID NO: 22 and activates SEQ ID NO: 22.

20 20. The method of Claim 19, wherein said interferon- α treatable condition is selected from hepatitis B, hepatitis C, hepatitis D, T-cell leukemia-lymphoma, multiple myeloma, chronic myeloid leukemia, and systemic lupus erythematosus.

30 21. A method of treating a patient having an interferon- α treatable condition, comprising administering to the patient an antibody or antibody fragment which binds specifically to SEQ ID NO: 41 and activates SEQ ID NO: 41.

22. The method of Claim 21, wherein said interferon- α treatable condition is selected from hepatitis B, hepatitis C, hepatitis D, T-cell leukemia-lymphoma, multiple myeloma, chronic myeloid leukemia, and systemic lupus erythematosus.

SEQUENCE SUBMISSION

SEQ ID NO: 1 provides primate TLR1 nucleotide sequence.
5 SEQ ID NO: 2 provides primate TLR1 polypeptide sequence.
SEQ ID NO: 3 provides primate TLR2 nucleotide sequence.
SEQ ID NO: 4 provides primate TLR2 polypeptide sequence.
SEQ ID NO: 5 provides primate TLR3 nucleotide sequence.
10 SEQ ID NO: 6 provides primate TLR3 polypeptide sequence.
SEQ ID NO: 7 provides primate TLR4 nucleotide sequence.
SEQ ID NO: 8 provides primate TLR4 polypeptide sequence.
SEQ ID NO: 9 provides primate TLR5 nucleotide sequence.
SEQ ID NO: 10 provides primate TLR5 polypeptide sequence.
15 SEQ ID NO: 11 provides primate TLR6 nucleotide sequence.
SEQ ID NO: 12 provides primate TLR6 polypeptide sequence.
SEQ ID NO: 13 provides rodent TLR6 nucleotide sequence.
20 SEQ ID NO: 14 provides rodent TLR6 polypeptide sequence.
SEQ ID NO: 15 provides primate TLR7 nucleotide sequence.
SEQ ID NO: 16 provides primate TLR7 polypeptide sequence.
SEQ ID NO: 17 provides primate TLR7 nucleotide sequence.
25 SEQ ID NO: 18 provides primate TLR7 polypeptide sequence.
SEQ ID NO: 19 provides primate TLR8 nucleotide sequence.
SEQ ID NO: 20 provides primate TLR8 polypeptide sequence.
SEQ ID NO: 21 provides primate TLR9 nucleotide sequence.
30 SEQ ID NO: 22 provides primate TLR9 polypeptide sequence.
SEQ ID NO: 23 provides primate TLR10 nucleotide sequence.
SEQ ID NO: 24 provides primate TLR10 polypeptide sequence.
SEQ ID NO: 25 provides primate TLR4 nucleotide sequence.
SEQ ID NO: 26 provides primate TLR4 polypeptide sequence.
SEQ ID NO: 27 provides rodent TLR6 nucleotide sequence.
35 SEQ ID NO: 28 provides rodent TLR6 polypeptide sequence.
SEQ ID NO: 29 provides rodent TLR6 nucleotide sequence.
SEQ ID NO: 30 provides rodent TLR6 polypeptide sequence.
SEQ ID NO: 31 provides primate TLR8 nucleotide sequence.
40 SEQ ID NO: 32 provides primate TLR8 polypeptide sequence.
SEQ ID NO: 33 provides primate TLR10 nucleotide sequence.
SEQ ID NO: 34 provides primate TLR10 polypeptide sequence.
SEQ ID NO: 35 provides rodent TLR10 nucleotide sequence.
SEQ ID NO: 36 provides primate TLR7 nucleotide sequence.
45 SEQ ID NO: 37 provides primate TLR7 polypeptide sequence.
SEQ ID NO: 38 provides primate TLR8 nucleotide sequence.
SEQ ID NO: 39 provides primate TLR8 polypeptide sequence.
SEQ ID NO: 40 provides primate TLR9 nucleotide sequence.
SEQ ID NO: 41 provides primate TLR9 polypeptide sequence.
SEQ ID NO: 42 provides primate TLR10 nucleotide sequence.
SEQ ID NO: 43 provides primate TLR10 polypeptide sequence.

SEQ ID NO: 44 provides rodent TLR10 nucleotide sequence.

SEQ ID NO: 45 provides rodent TLR10 polypeptide sequence.

2025 RELEASE UNDER E.O. 14176